RxDoctor Payments Data

Fernando Sanchez, MD

Infectious Disease · Laredo, TXNPI 1598863813

Payments from drug & device makers

$1,004in general payments, 2019–2025

Across 50 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Melinta Therapeutics, LLC$302
  • Gilead$175
  • Viiv Healthcare Company$155
  • Shionogi Inc$114
  • Merck$68
  • AbbVie$56
  • plus $134 from 5 others

What the payments were for

  • Food & beverage$1,004100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,004 in reported general payments places this provider in the 55th percentile of 576 infectious disease providers in Texas.

See all infectious disease providers in Texas

Medicare billing

Part B allowed, 2024
$161,526
Medicare patients
437
Services billed
2,089

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala189$723,046
EpclusaSofosbuvir/Velpatasvir22$523,325
StribildElviteg/Cob/Emtri/Tenofo Disop20$87,402
TriumeqAbacavir/Dolutegravir/Lamivudi20$77,967
DovatoDolutegravir Sodium/Lamivudine22$71,047
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf13$67,730
TivicayDolutegravir Sodium19$35,863
Daptomycin53$34,893
IsentressRaltegravir Potassium16$32,175
DescovyEmtricitabine/Tenofov Alafenam11$21,306
ErtapenemErtapenem Sodium23$8,333
Lamivudine-ZidovudineLamivudine/Zidovudine19$7,048
Fluconazole57$3,853
Valganciclovir Hcl11$3,676
Methenamine Hippurate22$2,668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Epclusa, Stribild, Descovy$175$1,355,078242 claims
Viiv Healthcare CompanyTriumeq, Dovato, Tivicay$155$184,87761 claims
MerckIsentress$68$32,17516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 576 infectious disease providers in Texas.

Other infectious disease in Laredo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →